A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Participants With KRASG12C Mutant Advanced Solid Tumors
This is a study evaluating the efficacy, safety, and pharmacokinetics of MK-1084 in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and